Uterine Corpus Sarcoma — Trials

Uterine Corpus Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 22
Ph III recruiting: 4
Growth YoY: —
Industry share: 15%
Top sponsor: Assistance Publique Hopitaux De Marseille
Termination share: 24.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 51–58 of 58 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00853567	Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids	terminated	Phase 3	71	Repros Therapeutics Inc.INDUSTRY	1	Aug 21, 2014	clinicaltrials
NCT01069120	Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids	terminated	Phase 3	27	Repros Therapeutics Inc.INDUSTRY	1	Aug 21, 2014	clinicaltrials